Ep. 254, Chapter 1: Michelle Werner, Alltrna
00:00 – 13:02
Life Science Leader Chief Editor Ben Comer, joined by Advancing RNA Editorial and Community Director Anna Rose Welch, interviews Michelle Werner, CEO of Alltrna, which develops transfer RNA (tRNA) oligonucleotide therapies. Werner joined Alltrna following her son's diagnosis with Duchenne muscular dystrophy in 2020. She was drawn to the company’s unique platform, which aims to use a single engineered tRNA to address numerous different diseases, a significant departure from the one-disease-at-a-time approach of modalities like gene therapy. Werner also discusses the transition from a commercial role to leading a biotech startup, particularly the challenges of fundraising and managing a team of scientists.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.